Clinical trial
A Randomised, Double-blind, Double-dummy, Multicentre, Phase III, Non Inferiority Trial of an Oral Mesalazine Formulation in Patients With Active Mild to Moderate Ulcerative Colitis for the Induction of Remission.
NCT06176560 is registered in ClinicalTrials.gov with Faes Farma, S.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomised, Double-blind, Double-dummy, Multicentre, Phase III, Non Inferiority Trial of an Oral Mesalazine Formulation in Patients With Active Mild to Moderate Ulcerative Colitis for the Induction of Remission.
- Lead sponsor
- Faes Farma, S.A.
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- March 31, 2024
- Completion date
- August 31, 2025
- Enrollment
- 376 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.